Mobia Medical, Inc. 8K

Mobia Medical, Inc. announced strong second quarter 2026 revenue growth, higher operating losses, a substantially increased cash position from its recent IPO, updated full-year revenue guidance, and new board appointments.

On August 11, 2026, Mobia Medical, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighting revenue growth of 102% year-over-year to $13.5 million driven by increased adoption of its Vivistim Paired VNS System, gross margin of 83.2%, an increased net loss of $21.0 million due to higher operating expenses to support commercial expansion and development, and a strengthened balance sheet with $177.1 million in cash and cash equivalents following its May 2026 initial public offering that generated approximately $134.0 million in net proceeds; the company also provided full‑year 2026 revenue guidance of $54–56 million, announced the publication of two‑year VNS‑REHAB follow‑up data, and disclosed the appointment of Myriam Curet, M.D. and Reza Zadno, Ph.D. to its Board of Directors.

Filing Facts

CIK

1489993

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-344666

Alert Tier

7